Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma

SIMPLE SUMMARY: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with more than 500,000 new cases diagnosed annually. Surgical resection, chemoradiotherapy, targeted therapy, and immunotherapy have been approved for HNSCC treatment. While a minority of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Guiqin, Shan, Liang, Liu, Yuanyi, Wu, Tzyy-Choou, Gu, Xinbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027470/
https://www.ncbi.nlm.nih.gov/pubmed/35453686
http://dx.doi.org/10.3390/biology11040486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027470/
https://www.ncbi.nlm.nih.gov/pubmed/35453686
http://dx.doi.org/10.3390/biology11040486

Ejemplares similares